The Safety of an Adenosine A1-Receptor Antagonist, Rolofylline, in Patients with Acute Heart Failure and Renal Impairment
详细信息 查看全文
- 作者：Professor John R. Teerlink (1)
Vicente J. Iragui (2)
Jay P. Mohr (3)
Peter E. Carson (4)
Paul J. Hauptman (5)
David H. Lovett (1)
Alan B. Miller (6)
Ileana L. Pi?a (7)
Scott Thomson (8)
Paul D. Varosy (9)
Michael R. Zile (10)
John G. F. Cleland (11)
Michael M. Givertz (12)
Marco Metra (13)
Piotr Ponikowski (14)
Adriaan A. Voors (15)
Beth A. Davison (16)
Gad Cotter (16)
Denise Wolko (17)
Paul DeLucca (17)
Christina M. Salerno (18)
George A. Mansoor (19)
Howard Dittrich (20)
Christopher M. O’Connor (1)
Barry M. Massie - 刊名：Drug Safety
- 出版年：2012
- 出版时间：March 2012
- 年：2012
- 卷：35
- 期：3
- 页码：233-244
- 全文大小：191KB
- 参考文献：1. Kiesman WF, Elzein E, Zablocki J. A1 adenosine receptor antagonists, agonists, and allosteric enhancers. Handb Exp Pharmacol 2009; 193: 25-8 CrossRef
2. Boison D. Adenosine and epilepsy: from therapeutic rationale to new therapeutic strategies. Neuroscientist 2005 Feb; 11 (1): 25-6 CrossRef
3. Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study: a randomized, placebo-controlled, dosefinding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008 Oct; 14 (8): 631-0 CrossRef
4. Weatherley BD, Cotter G, Dittrich HC, et al. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 2010 Jan; 16 (1): 25-5 CrossRef
5. Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363 (15): 1419-8 CrossRef
6. Kunitz SC, Gross CR, Heyman A, et al. The pilot Stroke Data Bank: definition, design, and data. Stroke 1984 Jul-Aug; 15 (4): 740-
7. Adams Jr HP, Bendixen BH, Kappelle LJ, et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 Jan; 24 (1): 35-1 CrossRef
8. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985 Apr-Jun; 4 (2): 213-6
9. Cleland JG, Freemantle N, Coletta AP, et al. Clinical trials update from the American Heart Association: REPAIRAMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006 Jan; 8 (1): 105-0 CrossRef
10. Felker GM, Benza RL, Chandler AB, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J Am Coll Cardiol 2003 Mar 19; 41 (6): 997-003 CrossRef
11. VMAC Investigators. Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA2002Mar 27; 287 (12): 1531-0
12. Fredholm BB, Chen JF, Masino SA, et al. Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 2005; 45: 385-12 CrossRef
13. Boison D. The adenosine kinase hypothesis of epileptogenesis. Prog Neurobiol 2008 Mar; 84 (3): 249-2 CrossRef
14. Ribeiro JA. What can adenosine neuromodulation do for neuroprotection? Curr Drug Targets CNS Neurol Disord 2005 Aug; 4 (4): 325-9 CrossRef
15. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol 2007 Oct 16; 50 (16): 1551-0 CrossRef
16. Dittrich HC, Gupta DK, Hack TC, et al. The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment. J Card Fail 2007 Oct; 13 (8): 609-7 CrossRef
17. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators. Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. JAMA 1998 Apr 22-9; 279 (16): 1265-2
18. Sherman DG, Dyken Jr ML, Gent M, et al. Antithrombotic therapy for cerebrovascular disorders: an update. Chest 1995 Oct; 108 (4 Suppl.): 444-6S CrossRef
19. Mohr JP, Thompson JL, Lazar RM, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl JMed 2001 Nov 15; 345 (20): 1444-1 CrossRef
20. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007 Nov 7; 298 (17): 2009-9 CrossRef
21. Greenberg B, Thomas I, Banish D, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study. J Am Coll Cardiol 2007 Aug 14; 50 (7): 600- CrossRef
22. Suzuki T, Hirata K, Elkind MS, et al. Metabolic syndrome, endothelial dysfunction, and risk of cardiovascular events: the Northern Manhattan Study (NOMAS). Am Heart J 2008 Aug; 156 (2): 405-0 CrossRef
23. Kitagawa H, Mori A, Shimada J, et al. Intracerebral adenosine infusion improves neurological outcome after transient focal ischemia in rats. Neurol Res 2002 Apr; 24 (3): 317-3 CrossRef
24. Fantidis P. The role of intracellular 3--cyclic adenosine monophosphate (cAMP) in atherosclerosis. Curr Vasc Pharmacol 2010 Jul; 8 (4): 464-2 CrossRef
25. Sebastiao AM, Ribeiro JA. Adenosine receptors and the central nervous system. Handb Exp Pharmacol 2009; 193: 471-34 CrossRef
26. Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb Exp Pharmacol 2009; 193: 535-7 CrossRef - 作者单位：Professor John R. Teerlink (1)
Vicente J. Iragui (2)
Jay P. Mohr (3)
Peter E. Carson (4)
Paul J. Hauptman (5)
David H. Lovett (1)
Alan B. Miller (6)
Ileana L. Pi?a (7)
Scott Thomson (8)
Paul D. Varosy (9)
Michael R. Zile (10)
John G. F. Cleland (11)
Michael M. Givertz (12)
Marco Metra (13)
Piotr Ponikowski (14)
Adriaan A. Voors (15)
Beth A. Davison (16)
Gad Cotter (16)
Denise Wolko (17)
Paul DeLucca (17)
Christina M. Salerno (18)
George A. Mansoor (19)
Howard Dittrich (20)
Christopher M. O’Connor (1)
Barry M. Massie
1. San Francisco Veterans Affairs Medical Center and University of California, San Francisco, San Francisco, CA, USA
2. University of California, San Diego, San Diego, CA, USA
3. Columbia University College of Physicians and Surgeons, New York, NY, USA
4. Washington DC Veterans Affairs Medical Center and Georgetown University, Washington, DC, USA
5. St Louis University School of Medicine, St Louis, MO, USA
6. University of Florida Health Science Center, Jacksonville, Jacksonville, FL, USA
7. Cleveland Veterans Affairs Medical Center and Case Western Reserve University, Cleveland, OH, USA
8. San Diego Veterans Affairs Medical Center University of California, San Diego, San Diego, CA, USA
9. Veterans Affairs Eastern Colorado Health Care System and University of Colorado Denver, Denver, CO, USA
10. RHJ Department of Veterans Affairs Medical Center and Medical University of South Carolina, Charleston, SC, USA
11. University of Hull, Kingston Upon Hull, UK
12. Brigham and Women’s Hospital, Boston, MA, USA
13. University of Brescia, Brescia, Italy
14. Medical University, Clinical Military Hospital, Wroclaw, Poland
15. University Medical Center Groningen, Groningen, the Netherlands
16. Momentum Research, Inc., Durham, NC, USA
17. Merck Research Laboratories, North Wales, PA, USA
18. Merck Research Laboratories, Rahway, NJ, USA
19. NovaCardia, Inc., San Diego, CA, USA
20. Duke University Medical Center, Durham, NC, USA - ISSN：1179-1942
文摘
Background: Adenosine exerts actions in multiple organ systems, and adenosine receptors are a therapeutic target in many development programmes. Objective: The aim of this analysis was to evaluate the safety of rolofylline, an adenosine A1-receptor antagonist, in patients with acute heart failure. Methods: The effect of rolofylline was investigated in patients hospitalized for acute heart failure with impaired renal function. Intravenous rolofylline 30 mg or placebo was infused over 4 hours daily for up to 3 days. Adverse events (AEs) and serious AEs (SAEs) were recorded from baseline through 7 and 14 days, respectively, and clinical events were adjudicated through 60 days. Results: Of 2033 patients enrolled, 2002 received study drug randomized 2 : 1 to rolofylline or placebo. Rolofylline and placebo were associated with a similar risk of pre-specified groups of AEs or SAEs, other than selected neurological events. Investigator-reported seizures occurred in 11 (0.8%) rolofylline-treated patients and zero patients receiving placebo (p = 0.02). Stroke occurred in 21 (1.6%) patients assigned to rolofylline compared with 3 (0.5%) placebo-treated patients through 60 days with a greater risk for stroke in the rolofylline group (hazard ratio 3.49; 95% CI 1.04, 11.71; p = 0.043). There was no temporal relation to rolofylline administration and no specific stroke subtype or clinical characteristics that predicted stroke in the rolofylline group. Conclusions: Rolofylline treatment was associated with an increased seizure rate, an anticipated complication of A1-receptor antagonists. An unanticipated, disproportionate increase in strokes in the rolofylline-treated patients emerged, although no clear temporal relation, aetiology, stroke subtype or interacting factor suggestive of a causal mechanism was identified. Further research into stroke as a potential complication of adenosine-modulating therapies is required. Additionally, this study underscores the value of longer follow-up durations for AEs, even for agents with short treatment periods, such as in acute heart failure. Trial Registration: ClinicalTrials.gov identifiers NCT00328692 and NCT00354458.